MedTrace Logo

Effect of Alpha Lipoic Acid on Obesity Related Comorbidities

NCT00994513 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 70

Last updated 2010-09-24

No results posted yet for this study

Summary

The major objective of this study is to conduct a double-blind, placebo-controlled, randomized clinical trial to assess whether oral alpha lipoic acid supplementation will decrease cardiovascular disease and type 2 diabetes risk in obese subjects.

Conditions

Interventions

DIETARY_SUPPLEMENT

Alpha Lipoic Acid

1200 mg/day

DIETARY_SUPPLEMENT

Placebo

1200 mg/day

Sponsors & Collaborators

  • Xinjiang Medical University

    collaborator OTHER

  • Augusta University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00994513 on ClinicalTrials.gov